• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Acutus Medical to Announce Second Quarter 2023 Financial Results

    7/24/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email

    CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

    To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

    The live webinar of the call may be accessed by visiting the Events section of the Acutus investor relations website at ir.acutusmedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

    About Acutus Medical, Inc.

    Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

    Investor Contact

    Caroline Corner

    ICR Westwicke

    D: 415-202-5678

    [email protected]

    Media Contact

    Rhiannon Pickus

    442-232-6094

    [email protected]



    Primary Logo

    Get the next $AFIB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acutus Medical Reports Full Year 2024 Financial Results

    CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas

    3/24/25 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Announces Operational Downsizing

    CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag

    12/4/24 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

    CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi

    11/14/24 4:26:42 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director by deputization Flynn James E

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    1/28/25 9:00:08 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mukai Takeo covered exercise/tax liability with 8,475 units of Form 4, decreasing direct ownership by 10% to 72,874 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    3/4/24 5:20:05 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sohn Tom covered exercise/tax liability with 7,582 units of Form 4, decreasing direct ownership by 7% to 105,009 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    2/7/24 4:12:59 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    SEC Filings

    View All

    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 10-K filed by Acutus Medical Inc.

    10-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 5:27:27 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 4:07:31 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

    SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    1/28/25 5:40:03 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by BTIG

    BTIG downgraded Acutus Medical from Buy to Neutral

    1/20/22 9:29:42 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously

    1/14/22 8:31:41 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by JP Morgan

    JP Morgan downgraded Acutus Medical from Neutral to Underweight

    11/15/21 7:17:46 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Leadership Updates

    Live Leadership Updates

    View All

    Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

    CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr

    1/9/23 6:00:00 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Acutus Medical Appoints Niamh Pellegrini to Board of Directors

    CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu

    8/12/21 4:02:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Financials

    Live finance-specific insights

    View All

    Acutus Medical to Cancel Third Quarter 2023 Conference Call

    CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

    11/10/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical to Announce Third Quarter 2023 Financial Results

    CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

    11/2/23 4:13:07 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Second Quarter 2023 Financial Results

    CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil

    8/7/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

    SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

    11/14/24 1:03:20 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Acutus Medical Inc.

    SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

    5/17/24 5:20:26 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care